利用床旁生命体征轨迹识别COVID-19亚表型
本研究为多中心队列研究,纳入2020年3月1日至2022年5月31日Emory Healthcare系统四家学术医院收治的7065例成人COVID-19患者,使用已验证的基于组的轨迹模型,根据入院8小时内的口腔温度、心率、呼吸频率及收缩压和舒张压将患者分为四个亚型。A组(n=1429,20%)为高体温、心率、呼吸频率伴低血压;B组(n=1454,21%)为高体温、心率、呼吸频率伴高血压;C组(n=2996,42%)为低体温、心率、呼吸频率伴血压正常;D组(n=1186,17%)为低体温、心率、呼吸频率伴低血压。A组和D组机械通气、血管加压药使用及30天住院死亡率的OR更高(P<.001)。在接受托珠单抗治疗(n=55)与符合托珠单抗标准但在其使用前入院(n=461)的患者比较中,托珠单抗与30天死亡率的相关性在各亚型间存在显著异质性(P=.001)。作者认为,利用低资源环境下也可获得的床旁生命体征,可识别与COVID-19不同表现相关的亚型,可能有助于抢先和靶向治疗。
要点
- 入院8小时内口腔温度、心率、呼吸频率及收缩压和舒张压的轨迹可将住院COVID-19患者分为4个亚型。
- A组(n=1429,20%)为高体温、心率、呼吸频率伴低血压;D组(n=1186,17%)为低体温、心率、呼吸频率伴低血压。
- A组和D组机械通气、血管加压药使用及30天住院死亡率的OR更高(P<.001)。
- 托珠单抗与30天死亡率的相关性在各亚型间存在显著异质性(P=.001),比较的是接受托珠单抗n=55与符合标准但使用前入院n=461的患者。
- 作者认为床旁生命体征轨迹可在低资源环境下识别COVID-19亚型,可能有助于抢先和靶向治疗。
适用人群与场景
- 2020年3月1日至2022年5月31日Emory Healthcare系统四家学术医院收治的成人COVID-19住院患者,共7065例。
诊断标准与关键阈值
- 使用已验证的基于组的轨迹模型,根据入院8小时内的口腔温度、心率、呼吸频率及收缩压和舒张压进行分类。
研究设计与关键结果
- 研究类型为多中心队列研究,纳入四家学术医院7065例成人COVID-19住院患者,使用基于组的轨迹模型根据入院8小时内生命体征分类。
- 共识别四个亚型:A组(n=1429,20%)高体温、心率、呼吸频率伴低血压;B组(n=1454,21%)高体温、心率、呼吸频率伴高血压;C组(n=2996,42%)低体温、心率、呼吸频率伴血压正常;D组(n=1186,17%)低体温、心率、呼吸频率伴低血压。
- A组和D组机械通气、血管加压药使用及30天住院死亡率的OR更高(P<.001)。
- 接受托珠单抗患者(n=55)与符合托珠单抗标准但在其使用前入院患者(n=461)比较,托珠单抗与30天死亡率的相关性在各亚型间存在显著异质性(P=.001)。
证据类型、等级与局限
- 证据类型:多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,利用低资源环境下也可获得的床旁生命体征轨迹,可识别与COVID-19不同表现相关的亚型,可能有助于抢先和靶向治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trajectories of bedside vital signs have been used to identify sepsis subphenotypes with distinct outcomes and treatment responses. The objective of this study was to validate the vitals trajectory model in a multicenter cohort of patients hospitalized with COVID-19 and to evaluate the clinical characteristics and outcomes of the resulting subphenotypes.
RESEARCH QUESTION: Can the trajectory of routine bedside vital signs identify COVID-19 subphenotypes with distinct clinical characteristics and outcomes?
STUDY DESIGN AND METHODS: The study included adult patients admitted with COVID-19 to four academic hospitals in the Emory Healthcare system between March 1, 2020, and May 31, 2022. Using a validated group-based trajectory model, we classified patients into previously defined vital sign trajectories using oral temperature, heart rate, respiratory rate, and systolic and diastolic BP measured in the first 8 h of hospitalization. Clinical characteristics, biomarkers, and outcomes were compared between subphenotypes. Heterogeneity of treatment effect to tocilizumab was evaluated.
RESULTS: The 7,065 patients with hospitalized COVID-19 were classified into four subphenotypes: group A (n = 1,429, 20%)-high temperature, heart rate, respiratory rate, and hypotensive; group B (1,454, 21%)-high temperature, heart rate, respiratory rate, and hypertensive; group C (2,996, 42%)-low temperature, heart rate, respiratory rate, and normotensive; and group D (1,186, 17%)-low temperature, heart rate, respiratory rate, and hypotensive. Groups A and D had higher ORs of mechanical ventilation, vasopressors, and 30-day inpatient mortality (P < .001). On comparing patients receiving tocilizumab (n = 55) with those who met criteria for tocilizumab but were admitted before its use (n = 461), there was significant heterogeneity of treatment effect across subphenotypes in the association of tocilizumab with 30-day mortality (P = .001).
INTERPRETATION: By using bedside vital signs available in even low-resource settings, we found novel subphenotypes associated with distinct manifestations of COVID-19, which could lead to preemptive and targeted treatments.
参考来源
- Bhavani SV, Robichaux C, Verhoef PA, et al. Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes. Chest. 2023. PMID: 37748574. doi:10.1016/j.chest.2023.09.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。